A population-based serological survey of *Vibrio cholerae* **antibody titers in Ouest Department, Haiti in the year prior to the 2022 cholera outbreak**

Authors:

Christy H. Clutter^{1,2,#}, Molly B. Klarman^{3,#}, Youseline Cajusma³, Emilie T. Cato³, Md. Abu Sayeed³, Lindsey Brinkley³, Owen Jensen², Chantale Baril⁴, V. Madsen Beau De Rochars⁵, Andrew S. Azman⁶, Maureen T. Long^{7,8}, Derek Cummings^{7,8}, Daniel T. Leung^{1,2,*}, Eric J. Nelson7,8*

¹Division of Infectious Disease, University of Utah, Salt Lake City, Utah, USA

²Division of Microbiology & Immunology, University of Utah, Salt Lake City, Utah, USA

³University of Florida, Departments of Pediatrics and Environmental and Global Health, Gainesville, Florida, USA

4 Université d'État d'Haïti (UEH), Port au Prince, Haiti

⁵Department of Health Services Research, Management and Policy, School of Public Health and Health Professions, University of Florida, Gainesville, Florida, USA

⁶Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA

⁷Department of Comparative Diagnostic and Population Medicine, College of Veterinary Medicine, University of Florida, Gainesville, Florida, USA

8 University of Florida, Emerging Pathogens Institute, Gainesville, Florida, USA

These first authors contributed equally to this article

*These senior authors contributed equally to this article

Corresponding author:

Christy H. Clutter. Division of Microbiology and Immunology, University of Utah. Salt Lake City, Utah, USA Email: christy.clutter@hsc.utah.edu

Key words: Cholera, Haiti, Outbreak, Serosurvey, ELISA, Vibriocidal, Correlates of Protection, Dried Blood Spots

ABSTRACT

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.02.06.23285537;](https://doi.org/10.1101/2023.02.06.23285537) this version posted February 8, 2023. The copyright holder for this preprint

INTRODUCTION

 In October 2010, the UN peacekeeping mission accidentally introduced cholera into post- earthquake Haiti (1–6). Over the next nine years, approximately 820,000 cholera cases and 10,000 deaths were recorded (7). A response was ultimately organized through a national elimination plan (8), and the last confirmed case of cholera was reported in late January of 2019 (9). In February of 2022, following a 3-year period with no confirmed cases, the Haitian Ministry of Health was optimistic that cholera elimination had been achieved (10). Unfortunately, 10 months later, in a period of instability that compromised access to clean water and sanitation, 21 two cases of cholera were confirmed on October 2nd of 2022 and a new outbreak started, which as of January 31, 2023, had led to more than 27,000 suspected cases and 560 registered deaths (11).

 Phylogenetic analyses suggested the current strain was a descendent of the *Vibrio cholerae* O1 Ogawa strain responsible for the original outbreak (12,13). Combatting this new outbreak is challenged by security and humanitarian crises (14,15); however, legacy knowledge 27 and infrastructure remain from the previous outbreak (16,17). There may also be protective immunity afforded by prior infection or vaccination. In the absence of ongoing transmission, younger populations not present in the prior outbreak period would be immunologically naïve and at higher risk of infection. This hypothesis is supported by a report of high rates of young children presenting with cholera (18).

 Upon exposure to toxigenic *V. cholerae*, the adaptive antibody response is dominated by two epitopes: cholera toxin and lipopolysaccharide (LPS) (19). However, the most clearly defined non-mechanistic correlate of protection for cholera is the presence of vibriocidal antibodies. These antibodies are functional bactericidal antibodies that target the O-specific

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.02.06.23285537;](https://doi.org/10.1101/2023.02.06.23285537) this version posted February 8, 2023. The copyright holder for this preprint

 Sampling and randomization. Households were randomly sampled geographically and proportionally to population density across the 477 sq km study area. A sampling grid was constructed inside the study area with 149 total grid cells using ArcGIS (ESRI). Grid cells were stratified by population density (low 0-399, medium 400-1511, high 1512-4664) and the sample schema was established *a priori*. Twenty-five grid cells were randomly chosen proportional to population density (2 low, 5 medium, 18 high). An additional 6 low density grid cells were added to have statistical power to conduct future stratified analyses on population density effects. Logistical constraints resulted in 25 grid-cells sampled (6 low, 3 medium, 15 high) out of the 31 intended to be sampled. Within each grid cell sampled, 21 points were randomly distributed and enclosed by Thiessen polygons. Within each polygon, one household was enrolled and sampled; the intention was to enroll from 18 of the 21 polygons per selected grid cell; the remaining 3 were used as 'back-up' polygons. The order that grid cells were sampled was randomized. **Participant recruitment.** Haitian staff navigated to each grid cell and polygon (via car, motorcycle, or foot) using ArcGIS Collector (ESRI). The first household reached upon entering the targeted polygon was screened. If the household declined participation or was ineligible, screening continued by proceeding to the next closest house, while remaining within the polygon. A 'spin the bottle' app was used to determine the 'closest' house if there were multiple equidistant neighboring houses. This process was repeated until either one household was enrolled per polygon (18 total per grid cell) or all households within the polygon were screened. **Participant inclusion criteria, consent process, and incentives.** Eligibility criteria included a household with one adult head of household (HoH) who provided written consent to complete a household survey and at least two household members who provided written consent to provide a dried blood spot (DBS) sample and respond to a household member survey. Parents/guardians 18

81 vears and older provided consent for their minor children and children \geq 7 years provided assent. Households with a single member were eligible if both consent for the surveys and DBS sample were provided. There was no lower age limit for eligibility. A 500 Gourde (\$4.50 US) phone credit was provided to HoH participants to facilitate contact with the study hotline for questions. **Sample collection.** DBS sampling was performed by finger stick, or heel stick in children <1 year, and spotted onto Whatman 903 Protein Saver cards. **Data collection.** The HoH survey queried family demographics and socioeconomic status. The household member survey asked about current and past symptoms and history relating to diarrheal syndromes. Vaccination and disease history were self-reported. Children under 5 years were measured for basic parameters of malnutrition (mid-upper arm circumference (MUAC), weight, and height).

DBS Eluates. Using a hole puncher, nine 6mm spots were punched from the blood circles on

93 each DBS card and placed into a microcentrifuge tube containing 600 µL of a 1X PBS-Tween

94 solution. The samples were then placed on a tube rocker at speed 50 rpm overnight at 4° C. The

next day the samples were centrifuged at 10,500 x g for 2 minutes. The supernatant was removed

and stored at -80°C until ready for further use.

ELISA. Enzyme-linked immunosorbent assays (ELISAs) were performed on all DBS specimens

(n=861). Nunc Maxisorp flat-bottom plates (Sigma-Aldrich) were coated overnight with either *V.*

cholerae O1 Ogawa-specific LPS (gift of Edward Ryan, Massachusetts General Hospital) or

100 monosialoganglioside (GM₁, Sigma-Aldrich) at 1 μ g/mL. Plates that had been coated with GM₁

were washed in phosphate buffered saline (PBS) with 0.05% Tween20 (PBST), blocked in PBST

 $102 + 1\%$ bovine serum albumin (BSA), and coated for a second night in cholera toxin subunit B

(CtxB, Sigma-Aldrich) at 2.5 µg/mL. Following coating, plates were blocked, incubated with

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.02.06.23285537;](https://doi.org/10.1101/2023.02.06.23285537) this version posted February 8, 2023. The copyright holder for this preprint

 DBS eluates that were diluted 1:7.5 in PBST + 0.1% BSA, incubated in 1:1000 horseradish peroxidase (HRP) conjugated secondary antibody, either goat-anti-human IgG or IgA (Jackson ImmunoResearch), and developed in TMB substrate solution (Thermo Scientific). Immediately after addition of TMB, plates were placed on a BioTek ELx800 plate reader and read kinetically at 405nm once every minute for eight minutes. Maximum slope (MaxV) values were normalized against a positive control for each plate to generate ELISA units. Positive controls were convalescent plasma from confirmed cholera cases, diluted 1:100. Negative controls were naïve serum (Sigma-Aldrich), also diluted 1:100. **Vibriocidal antibody assay.** The criteria to select samples for vibriocidal antibody assays were those samples with an IgG ELISA titer two standard deviations above the mean for either LPS IgG or CtxB IgG. The assay was conducted via a previously described DBS eluate-adapted drop- plate vibriocidal method (30) and adapted for this study. *V. cholerae* O1 El Tor Ogawa strain (X25049) were grown overnight on thiosulfate-citrate-bile salts-sucrose (TCBS) *Vibrio*-selective agar, after which 2-3 colonies were cultured in Luria-Betani (LB) broth, washed several times 118 with sterile PBS and adjusted to an OD₆₀₀ of 0.3. DBS samples were diluted 1:5 in sterile PBS, heat-inactivated at 56°C, and then serially diluted 1:2 horizontally across a flat-bottom NunclonTM Delta Surface 96-well plate (Thermo Scientific). Each 96-well-plate included three growth controls and three negative controls. Each batch included at least one monoclonal antibody positive control. Samples and positive controls were cultured for 1hr in a growth 123 solution containing the normalized *V. cholerae* culture $(OD_{600} = 0.3)$ and guinea pig complement (Sigma-Aldrich). Negative controls were cultured with sterile PBS. Plate controls were 125 subsequently plated in 5µL drops onto LB agar. Positive control and participant samples were plated onto TCBS agar (selective media for *V. cholerae*) and cultured overnight at 37°C. Titers

 were determined as the reciprocal of the first dilution in which the culture drop shows serrated edges or individual colonies.

Statistical Analyses*.* Statistical comparisons between two populations were assessed with an

130 unpaired, two-tailed Student's t test. Significance was determined at $p \le 0.05$. Generalized

additive models (GAMs) with a spline to fit age were used to assess the relationship of age and

antibody distribution. R version 4.1.3 with the mgcv package was used to fit the splines.

RESULTS

In this cross-sectional serological survey, we collected DBS samples from 861 enrolled

adult (n=564) and child (<18 years, n=297) participants (Table 1); 62.6% were female. A small

percentage of participants self-reported prior cholera vaccination (n=10/861, 1.2%) or self-

reported clinical disease (n=37/861, 4.3%).

 Antibody titers for *V. cholerae* LPS and CtxB were measured across the population for both IgG and IgA isotypes (Figure 1A). Children less than 5 years old had significantly lower 140 titers of both LPS IgG and IgA (p<0.0001, Figure 2A-B, Supplemental Table 1) compared to 141 children and adults 5 and older. CtxB IgG was elevated in children under 5 ($p=0.0033$), 142 specifically within 1-2-year-old children (p=0.0024 and p=0.0011 respectively, Figure 2C). There was a significant difference between children under 5, older children, and adults with respect to CtxB IgA, but this was driven by the youngest children under 1 year of age, who may lack antibody for reasons unrelated to exposure (Figure 2D). Medians, p-values and interquartile ranges are presented in Supplemental Table 1. Using generalized additive model (GAM) based splines, we estimated a significant positive non-linear association of IgA isotypes with age (LPS: effective degrees of freedom (EDF) 3.4, p<2e-16; CtxB: EDF 2.0, p<e-16) (Supplemental Figure 1). This association was not significant for IgG isotypes (LPS: EDF 4.9, p=0.12; CtxB: EDF 1.0, p=0.13).

 Vibriocidal assays were conducted on the subset of participant samples (n=51/861, 5.9%) that had IgG titers for either LPS or CtxB at two standard deviations above the mean. No samples tested had detectable vibriocidal responses (Figure 1B).

DISCUSSION

 In this cross-sectional serological survey in a regional population within Haiti, we detected low rates of circulating IgG and IgA antibodies against lipopolysaccharide (LPS) and cholera toxin subunit B (CtxB). Within the context of increasing antibody response with age, children 1-4 years of age had lower antibody titers against LPS IgG and LPS IgA compared to adults and children over five. Children 1-2 years old had elevated titers of CtxB IgG, which may reflect the cross-reactive nature of CtxB antibodies with the heat-labile toxin (LT) of enterotoxigenic *Escherichia coli*, which has the highest force of infection (measured by seroconversion rate per child-year) among enteric pathogens in Haitian children (31). Due to the inherent cross-reactivity of CtxB, LPS IgG is more specific for exposure history to *V. cholerae* and IgG is more meaningful for age-related comparisons. However, no functional (vibriocidal) antibodies, which is the best available correlate of protection for cholera, were detected. The serologic assays used in our study have been demonstrated to be associated with prior infection with *V. cholerae* O1 based on longitudinal studies of culture-confirmed cholera

168 patients (21), and also demonstrated to be associated with protection against disease in studies of

household contacts of index cases and in human challenge studies (21,32,33). Our data are

consistent with limited recent disease transmission and antigenic exposure in this community,

 especially among young children that were born in the period with little to no circulating pandemic *V. cholerae*. These serologic data suggest that the Haitian communities surveyed may have limited pre-existing immunologic protection against cholera, especially among children under 5 years of age.

 The 2022 outbreak was caused by a *V. cholerae* Ogawa isolate that aligns with isolates circulating during the 2010-2019 outbreak (12,13). In the period between outbreaks, the degree to which *V. cholerae* circulated in human and environmental reservoirs at a level below the threshold detectable by the surveillance infrastructure is unknown. The intersection between low levels of circulating cholera and declining population immunity were likely important factors 180 that put Haiti at risk of this new outbreak. These factors, combined with the collapse of clean water and sanitation infrastructure, likely catalyzed the 2022 outbreak.

 The findings in this study must be considered within the context of the study limitations. First, there was a risk of enrollment bias because only 28% of the households screened consented to participate, which is lower than other studies in the area that employed similar recruitment methods (34); given oversampling among low density grid cells, the 'true' distribution across the population would need adjustment if these data are used as a baseline for future serosurveillance research. Second, the observations of lower IgA antibody titers in children 1-4 may be part of a larger trend of increasing IgA antibody responses with age, representing a confounding factor, and thus may not reflect specific exposures as hypothesized. Third, The ELISA was limited by the availability of quantitative and matrix-matched controls, leading to the use of convalescent plasma as a positive control, and naïve serum as a negative control. Fourth, the selection of samples with high ELISA units for vibriocidal assays may have missed samples with lower antibody levels but harboring functional antibodies. It is possible that matrix differences between

- two adjacent communes in the Ouest Department of Haiti, and our findings may not be
- generalizable to other locations in the country.

CONCLUSION

- In conclusion, our population-based serosurvey of two Haitian communities revealed a
- lack of functional antibodies, and significantly lower *V. cholerae* LPS-specific IgG antibodies
- among young children. Our findings suggest that populations in Haiti may be highly susceptible
- to cholera disease and outbreaks, especially among young children.

Acknowledgements

- We are grateful to the participants as well as the team who conducted the survey in Haiti. We
- would like to thank the administrators and leadership at the Emerging Pathogens Institute and the
- Department of Pediatrics at the University of Florida for their ongoing support. We also honor
- the dedication and support of the Ministry of Public Health and Population (Ministère de la Santé
- Publique et de la Population MSPP) for their commitment to the health of the Haitian
- population despite the profound period of instability.
- **Conflict of Interest Disclosures.** The authors declare that they have no competing interests.
- **Funding.** Funding for this study was provided through grant support to DTL from the National
- Institute of Allergy and Infectious Diseases (R01 AI135115) and EJN from the Children Miracle
- Network (Florida).
- **Role of the Funder/Sponsor:** The sponsors had no role in the design and conduct of the study;
- collection, management, analysis, and interpretation of the data; preparation, review, or approval
- of the manuscript; and decision to submit the manuscript for publication.

Abbreviations and Acronyms

- LPS Lipopolysaccharide
- CtxB Cholera toxin subunit B
- DBS Dried blood spot
- ELISA Enzyme-linked immunosorbent assay
- IgG, IgA Immunoglobulin G, Immunoglobulin A

223 **Table 1. Participant Characteristics**

224

225

227 **FIGURE 1**

228

229 **Figure 1.** *Vibrio cholerae* **specific and functional antibodies.** Enzyme-linked immunosorbent

230 assays (ELISAs) were performed on all 861 samples for LPS and CtxB, for both IgG and IgA 231 serotypes (A). Samples that were two standard deviations above the mean for LPS or CtxB IgG

232 $(n=51)$ were assayed for functional (vibriocidal) antibodies (B). Abbreviations: LPS =

233 lipopolysaccharide; $CtxB =$ cholera toxin subunit B. Median and interquartile ranges are

234 displayed (A).

236 **FIGURE 2**

237

238

239 **Figure 2. Antibody titers by age, vaccination status, and prior infection.** Antibody titers for

240 LPS and CtxB were compared between children under 5 years old (n=112) and adults and

241 children five and older for LPS IgG (A), LPS IgA (B), CtxB IgG (C) and CtxB IgA. Statistical

242 comparisons between \geq 5 and \leq 5 were made using an unpaired two-tailed student's t test.

243 Individual year-by-year comparisons were compared by one-way ANOVA. Significance is

244 annotated as follows: *p ≤ 0.05 , **p ≤ 0.01 ***p ≤ 0.001 ****p ≤ 0.0001 .

REFERENCES

- 1. Lantagne D, Balakrish Nair G, Lanata CF, Cravioto A. The Cholera Outbreak in Haiti: Where and How did it begin? In: Nair GB, Takeda Y, editors. Cholera Outbreaks [Internet]. Berlin, Heidelberg: Springer; 2014 [cited 2022 Dec 16]. p. 145–64. (Current Topics in Microbiology and Immunology). Available from: https://doi.org/10.1007/82_2013_331
- 2. Chin CS, Sorenson J, Harris JB, Robins WP, Charles RC, Jean-Charles RR, et al. The Origin of the Haitian Cholera Outbreak Strain. N Engl J Med. 2011 Jan 6;364(1):33–42.
- 3. Frerichs RR, Keim PS, Barrais R, Piarroux R. Nepalese origin of cholera epidemic in Haiti. Clin Microbiol Infect. 2012 Jun;18(6):E158–63.
- 4. Farmer P, Almazor CP, Bahnsen ET, Barry D, Bazile J, Bloom BR, et al. Meeting Cholera's Challenge to Haiti and the World: A Joint Statement on Cholera Prevention and Care. Small PLC, editor. PLoS Negl Trop Dis. 2011 May 31;5(5):e1145.
- 5. Piarroux R, Frerichs RR. Cholera and blame in Haiti. Lancet Infect Dis. 2015 Dec;15(12):1380–1.
- 6. Jenson D, Szabo V. Cholera in Haiti and Other Caribbean Regions, 19th Century. Emerg 261 Infect Dis. 2011 Nov; 17(11): 2130–5.
- 7. Cholera Haiti. Geneva, Switzerland: World Health Organization; 2022.
- 8. National plan for the elimination of cholera in Haiti; 2013-2022. Port au Prince, Haiti: Republic of Haiti Ministry of Public Health and Population National Directorate for Water Supply and Sanitation; 2013.
- 9. Santé WHO= O mondiale de la. Cholera 2019 Choléra 2019. Vol. 95, Weekly Epidemiological Record = Relevé épidémiologique hebdomadaire. World Health Organization = Organisation mondiale de la Santé; 2020. p. 441–8.
- 10. 4 février 2019 4 février 2022 trois (3) ans SANS CHOLÉRA en Haïti [Internet]. Le Ministère de la Communication Republique d'Haiti. 2022. Available from:
- https://www.communication.gouv.ht/2022/02/4-fevrier-2019-4-fevrier-2022-trois-3-ans-sans-cholera-en-haiti/
- 11. Epidemiological Update Cholera January 31, 2023 [Internet]. Pan American Health Organization / World Health Organization; 2023 Jan. Available from:
- https://www.paho.org/en/documents/epidemiological-update-cholera-31-january-2023
- 12. Rubin DHF, Zingl FG, Leitner DR, Ternier R, Compere V, Marseille S, et al. Reemergence of Cholera in Haiti. N Engl J Med. 2022 Nov 30;NEJMc2213908.

- 13. Mavian CN, Tagliamonte MS, Alam MT, Sakib SN, Cash MN, Riva A, et al. Re-emergence
- of cholera in Haiti linked to environmental *V. cholerae* O1 Ogawa strains [Internet].
- Infectious Diseases (except HIV/AIDS); 2022 Nov [cited 2022 Dec 19]. Available from: http://medrxiv.org/lookup/doi/10.1101/2022.11.21.22282526
- 14. Daniels JP. Cholera surges in Haiti. The Lancet. 2022 Dec;400(10367):1913.
- 15. Taylor L. Haiti's hospitals plan to close amid fuel shortages. BMJ. 2022 Oct 3;o2379.
- 16. Rebaudet S, Bulit G, Gaudart J, Michel E, Gazin P, Evers C, et al. The case-area targeted rapid response strategy to control cholera in Haiti: a four-year implementation study. Gurley E, editor. PLoS Negl Trop Dis. 2019 Apr 16;13(4):e0007263.
- 17. Rebaudet S, Dély P, Boncy J, Henrys JH, Piarroux R. Toward Cholera Elimination, Haiti. Emerg Infect Dis. 2021 Nov;27(11):2932–6.
- 18. Severe K, Alcenat N, Rouzier V. Resurgence of Cholera in Haiti amidst Humanitarian Crises. N Engl J Med. 2022 Nov 30;NEJMc2213782.
- 19. Kauffman RC, Bhuiyan TR, Nakajima R, Mayo-Smith LM, Rashu R, Hoq MR, et al. Single- Cell Analysis of the Plasmablast Response to Vibrio cholerae Demonstrates Expansion of Cross-Reactive Memory B Cells. mBio. 2016 Dec 20;7(6):e02021-16.
- 20. Aktar A, Rahman MA, Afrin S, Akter A, Uddin T, Yasmin T, et al. Plasma and memory B cell responses targeting O-specific polysaccharide (OSP) are associated with protection against Vibrio cholerae O1 infection among household contacts of cholera patients in Bangladesh. Small PLC, editor. PLoS Negl Trop Dis. 2018 Apr 23;12(4):e0006399.
- 21. Azman AS, Lessler J, Luquero FJ, Bhuiyan TR, Khan AI, Chowdhury F, et al. Estimating cholera incidence with cross-sectional serology. Sci Transl Med. 2019 Feb 20;11(480):eaau6242.
- 22. Iyer AS, Harris JB. Correlates of Protection for Cholera. J Infect Dis. 2021 Dec 20;224(Supplement_7):S732–7.
- 23. Bi Q, Ferreras E, Pezzoli L, Legros D, Ivers LC, Date K, et al. Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2017 Oct;17(10):1080–8.
- 24. Qadri F, Wierzba TF, Ali M, Chowdhury F, Khan AI, Saha A, et al. Efficacy of a Single- Dose, Inactivated Oral Cholera Vaccine in Bangladesh. N Engl J Med. 2016 May 5;374(18):1723–32.
- 25. Barzilay EJ, Schaad N, Magloire R, Mung KS, Boncy J, Dahourou GA, et al. Cholera Surveillance during the Haiti Epidemic — The First 2 Years. N Engl J Med. 2013 Feb 14;368(7):599–609.

- 26. Haiti Cholera figures; As of 31 January 2019. [Internet]. United Nations Office for the Coordination of Humanitarian Affairs.; 2019. Available from:
- https://www.humanitarianresponse.info/sites/www.humanitarianresponse.info/files/documen ts/files/ocha-hti-cholera-figures-20190131_en.pdf
- 27. Ivers LC, Teng JE, Lascher J, Raymond M, Weigel J, Victor N, et al. Use of Oral Cholera Vaccine in Haiti: A Rural Demonstration Project. Am J Trop Med Hyg. 2013 Oct 9;89(4):617–24.
- 28. Rouzier V, Severe K, Juste MAJ, Peck M, Perodin C, Severe P, et al. Cholera Vaccination in Urban Haiti. Am J Trop Med Hyg. 2013 Oct 9;89(4):671–81.
- 29. Haiti's Ministry of Health organizing a vaccination campaign against cholera in areas affected by Hurricane Matthew, supported by PAHO-WHO, UNICEF and other partners. Pan American Health Organization; 2016.
- 30. Iyer AS, Azman AS, Bouhenia M, Deng LO, Anderson CP, Graves M, et al. Dried Blood Spots for Measuring Vibrio cholerae-specific Immune Responses. Kosek M, editor. PLoS Negl Trop Dis. 2018 Jan 29;12(1):e0006196.
- 31. Arnold BF, Martin DL, Juma J, Mkocha H, Ochieng JB, Cooley GM, et al. Enteropathogen antibody dynamics and force of infection among children in low-resource settings. eLife. 2019 Aug 19;8:e45594.
- 32. Harris JB, LaRocque RC, Chowdhury F, Khan AI, Logvinenko T, Faruque ASG, et al. Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh. PLoS Negl Trop Dis. 2008 Apr 9;2(4):e221.
- 33. Haney DJ, Lock MD, Simon JK, Harris J, Gurwith M. Antibody-Based Correlates of Protection Against Cholera Analysis of a Challenge Study in a Cholera-Naïve Population. Clin Vaccine Immunol CVI. 2017 May 31;24(8):e00098-17, CVI.00098-17.
- 34. Klarman M, Schon J, Cajusma Y, Maples S, Beau de Rochars VEM, Baril C, et al. Opportunities to catalyse improved healthcare access in pluralistic systems: a cross-sectional study in Haiti. BMJ Open. 2021 Nov;11(11):e047367.
-
-
-
-
-